Viridian Therapeutics EPS Ratio 2011-2026 | VRDN

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Viridian Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-4.05	-6.66	-31.1	-1.34	-1.1	-1.38	-17.6	-1.4	-3.5	-12.2	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-1.1	-31.1	-8.04

Quarterly EPS Ratio Viridian Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-1.15	-1.02	-0.79	-	-1.09	-1.27	-1.61	-	-0.86	-1.06	-0.98	-	-1.25	-2.21	-2.91	-	-1.48	-1.82	-2.65	-0.31	-0.36	-0.29	-0.38	-0.33	-0.29	-0.29	-0.18	-0.29	-0.27	-0.34	-0.6	-9.2	-6.92	-5.88	-5.58	-	-0.39	-0.33	-0.45	-	-0.4	-4.73	-3.53	-	-0.35	-0.24	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.18	-9.2	-1.64

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
ACADIA Pharmaceuticals ACAD	1.37	$ 22.56	2.13 %	$ 3.74 B	USA
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-1.42	-	-	$ 8.42 M	USA
Akebia Therapeutics AKBA	-0.02	$ 1.43	3.62 %	$ 368 M	USA
argenx SE ARGX	-7.99	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Alnylam Pharmaceuticals ALNY	2.39	$ 327.25	2.42 %	$ 42.9 B	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Aytu BioScience AYTU	-2.16	$ 2.66	3.5 %	$ 16.7 M	USA
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	0.08	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	-0.53	$ 3.9	3.7 %	$ 9.38 B	Australia
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	2.1	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	-0.78	$ 4.18	1.21 %	$ 447 M	USA
Avid Bioservices CDMO	-2.23	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-26.8	-	-	$ 1.41 B	USA
Arcutis Biotherapeutics ARQT	-0.13	$ 24.61	5.76 %	$ 3.13 B	USA
Cabaletta Bio CABA	-2.1	$ 3.09	0.65 %	$ 310 M	USA
Checkpoint Therapeutics CKPT	-1.42	-	-	$ 169 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-2.84	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-2.33	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Autolus Therapeutics plc AUTL	-1.08	$ 1.49	9.56 %	$ 397 M	Britain
CTI BioPharma Corp. CTIC	-0.81	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	-6.45	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	-2.29	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	0.21	-	-	$ 2.02 B	USA
Forte Biosciences FBRX	-4.71	$ 26.27	0.38 %	$ 340 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	-0.09	$ 3.88	2.11 %	$ 261 B	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA